HC Wainwright Has Positive Outlook of MNPR FY2029 Earnings

Monopar Therapeutics Inc. (NASDAQ:MNPR) – Stock analysts at HC Wainwright upped their FY2029 earnings per share (EPS) estimates for Monopar Therapeutics in a note issued to investors on Friday, May 15th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of $1.88 for the year, up from their previous forecast of $1.79. The consensus estimate for Monopar Therapeutics’ current full-year earnings is ($3.03) per share.

MNPR has been the subject of several other reports. Wall Street Zen upgraded shares of Monopar Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, May 9th. Chardan Capital reiterated a “buy” rating and issued a $100.00 price objective on shares of Monopar Therapeutics in a report on Monday, March 30th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Monopar Therapeutics in a report on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and issued a $104.00 price objective on shares of Monopar Therapeutics in a report on Monday, February 23rd. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, January 21st. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $107.00.

Monopar Therapeutics Stock Down 1.6%

Shares of MNPR opened at $55.36 on Monday. The firm has a 50-day moving average price of $56.93 and a 200 day moving average price of $65.34. The firm has a market capitalization of $370.93 million, a PE ratio of -29.14 and a beta of 1.49. Monopar Therapeutics has a 52-week low of $28.40 and a 52-week high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Thursday, May 14th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.41.

Institutional Investors Weigh In On Monopar Therapeutics

Institutional investors have recently bought and sold shares of the business. Russell Investments Group Ltd. acquired a new stake in Monopar Therapeutics during the 3rd quarter worth about $28,000. BNP Paribas Financial Markets boosted its position in Monopar Therapeutics by 100.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after acquiring an additional 349 shares during the period. Meeder Asset Management Inc. acquired a new stake in Monopar Therapeutics during the 4th quarter worth about $65,000. JPMorgan Chase & Co. boosted its position in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Monopar Therapeutics during the 2nd quarter worth about $80,000. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics News Summary

Here are the key news stories impacting Monopar Therapeutics this week:

• Positive Sentiment: Monopar announced publication of a peer-reviewed Phase 2 study showing ALXN1840 significantly improved copper balance in patients with Wilson disease, which supports the company’s clinical pipeline and may boost confidence in its lead program. Article: Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
• Positive Sentiment: HC Wainwright and Brookline Capital Markets raised multiple earnings estimates for Monopar, including higher projections for FY2026, FY2027, FY2028, and FY2030, suggesting analysts see a better long-term earnings trajectory than before.
• Neutral Sentiment: The analyst revisions still leave Monopar with expected losses in the near term, so the changes may be viewed more as incremental optimism than a near-term fundamental turnaround.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.